哮喘联盟

   摘要
   哮喘是一种常见的慢性气道疾病，全世界有超过3亿哮喘患者。其中5%-10%为重症患者，反复急性加重导致的医疗成本和长期全身激素应用导致医疗分布不均匀。重症哮喘气道炎症表现导致靶向生化和小分子治疗药物的开发以期实现疾病控制，并尽可能减少激素相关合并症。本文综述目前可用药物，评价重症哮喘药物的发展以及对未来临床转归的影响。

 

（上海交通大学医学院附属瑞金医院呼吸与危重症医学科 周剑平 万欢英 摘译）

（Clin Exp Allergy. 2018 Jan 8. doi: 10.1111/cea.13086. [Epub ahead of print]）

 
 
New and emerging drug treatments for severe asthma.
 
Clin Exp Allergy. 2018 Jan 8. doi: 10.1111/cea.13086. [Epub ahead of print]
Diver S et al.

 
Abstract
Asthma is a common chronic inflammatory condition of the airways affecting over 300 million people worldwide. In 5-10% of cases it is severe, with disproportionate healthcare resource utilisation including costs associated with frequent exacerbations and the long-term health effects of systemic steroids. Characterisation of inflammatory pathways in severe asthma has led to development of targeted biological and small molecule therapies which aim to achieve disease control whilst minimising corticosteroid-associated morbidity. Herein we review currently licensed agents and those in development, and speculate how drug therapy for severe asthma might evolve and impact on clinical outcomes in the near future.